- Home
- ITGR vs ACAD Comparison
ITGR vs ACAD Comparison
Compare ITGR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITGR
- ACAD
- Stock Information
- Founded
- ITGR 1970
- ACAD 1993
- Country
- ITGR United States
- ACAD United States
- Employees
- ITGR N/A
- ACAD N/A
- Industry
- ITGR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- ITGR Health Care
- ACAD Health Care
- Exchange
- ITGR Nasdaq
- ACAD Nasdaq
- Market Cap
- ITGR 4.2B
- ACAD 3.8B
- IPO Year
- ITGR 2000
- ACAD 2004
- Fundamental
- Price
- ITGR $112.43
- ACAD $22.54
- Analyst Decision
- ITGR Strong Buy
- ACAD Buy
- Analyst Count
- ITGR 10
- ACAD 18
- Target Price
- ITGR $145.90
- ACAD $27.71
- AVG Volume (30 Days)
- ITGR 439.3K
- ACAD 2.1M
- Earning Date
- ITGR 07-24-2025
- ACAD 08-05-2025
- Dividend Yield
- ITGR N/A
- ACAD N/A
- EPS Growth
- ITGR N/A
- ACAD N/A
- EPS
- ITGR 2.18
- ACAD 1.37
- Revenue
- ITGR $1,746,192,000.00
- ACAD $996,283,000.00
- Revenue This Year
- ITGR $11.03
- ACAD $13.28
- Revenue Next Year
- ITGR $7.29
- ACAD $11.06
- P/E Ratio
- ITGR $51.43
- ACAD $16.50
- Revenue Growth
- ITGR 10.19
- ACAD 22.42
- 52 Week Low
- ITGR $104.93
- ACAD $13.40
- 52 Week High
- ITGR $146.36
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- ITGR 31.63
- ACAD 59.56
- Support Level
- ITGR $116.25
- ACAD $20.87
- Resistance Level
- ITGR $122.99
- ACAD $23.12
- Average True Range (ATR)
- ITGR 2.63
- ACAD 0.68
- MACD
- ITGR -0.79
- ACAD 0.04
- Stochastic Oscillator
- ITGR 10.81
- ACAD 75.32
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.